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Abstract  
Stem cells, as classically defined, are cells with a capacity to self-renew and to generate daughter cells that can 
differentiate down several cell lineages to form all of the cell types that are found in the mature tissue. Stem cells and 
tumour cells have many similar features, including infinite lifespan, self-renewal, multidrug resistance, telomerase 
expression and, in the instance of the prostate, androgen independence. Evidence supports a role for stem cells in the 
etiology of many types of cancer. The evolution of androgen-independent prostate carcinoma may reflect the 
emergence of stem like prostate tumour cells. Because cancer may be a disease of stem cell lineages and Shh-Gli 
signalling controls the behaviour of precursors and of cells with stem cell properties in the mammalian tissues, 
prostate cancer might derive from inappropriate expansion of prostatic epithelial stem cell lineages caused by 
abnormal Shh-Gli function. This review attempts to integrate these recent results. 
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Introduction 
Stem cells generally reside in specialised niches that form a microenvironment which maintains their 
primitive phenotype. Prostate stem cells may play a critical role in epithelial development and 
homeostasis. The proximal region and the urethra contain cells that regenerate prostatic tissue far more 
robustly than cells isolated from the intermediate or distal regions of ducts. These cells survive androgen 
ablation and regenerate prostatic tissue fully, once androgens are re-administered.  
 
Wnt signalling has been identified as one of the key signalling pathways in cancer, regulating cell 
growth, motility and differentiation. Because of its widespread activation in diverse human tumour 
diseases, the Wnt pathway has gained considerable and growing interest in prostate cancer research over 
recent years.  
 
A series of articles defined the role of Hh signalling in the growth and metastasis of advanced prostate 
cancer. Molecular mechanisms and pathway components discovered in biochemical, genetic and 
molecular studies of Hh signalling during development, particularly in stem cell biology, are now 
demonstrated to be behind characteristics of tumour cells such as proliferation and invasive behaviour.  
Developmental biology  
As a gland, the prostate is composed of many acini that empty into multiple tiny ductules, streaming 
toward posterior urethral termination in proximity to the seminal colliculus or verumontanum (veru). 
 
Normal development of prostatic ducts requires many coordinated cellular processes, including 
epithelial proliferation, ductal branching morphogenesis, ductal canalisation, and epithelial and 
mesenchymal differentiation. In many respects, ductal branching morphogenesis in the prostate resembles 
that of many other organs (e.g., mammary gland, lung, salivary gland and pancreas).  
 
Development of prostatic ducts begins when solid prostatic buds emerge from the urogenital sinus. 
These buds grow into the surrounding urogenital sinus mesenchyme.  
 
Today three histologically distinctive glandular zones are defined: peripheral (70–75%), central (20–
25%) and transition (5–10%) [1].  
 
The peripheral zone was characterised by ducts radiating laterally from the distal prostatic urethra 
(veru to apex) and was visualised as an extension coinciding with the ejaculatory duct axis.  
 
The central zone was a proximal wedge-shaped glandular region surrounding the ejaculatory ducts, 
broad laterally at the base of the prostate, and funnelling to duct orifices at the veru.  
 
A third zone, the transition zone, constituting less than 5% of the glandular prostate, was found to be 
com- posed of two separate gland groups bilateral to the urethra, just proximal to the veru.  
 
The human prostate, a tubuloalveolar gland in which ducts and acini have a similar secretory function, 
is pre- dominantly apocrine because the apical portion of the cell is cast off with some of its secretory 
products, especially enzymes.  
 
The acinar and ductal secretory epithelial cells pro- duce a great number of measurable substances, 
including acid phosphatase; lactic dehydrogenase; kallikrein proteases, such as prostate-specific antigen 
and HK-2; prostaglandin; spermine; fibrinogenase; aminopeptidase; zinc; citrate; cholesterol; tissue 
plasminogen activator; pepsinogen II; lactoferrin; and others [2, 3].  
 
  
Prostatic epithelial differentiation  
Prostatic development is a complex androgen-dependent process involving a coordinated set of events 
occurring in both the epithelial and stromal compartments of the gland. Thus, whereas epithelial 
differentiation is de- pendent on the presence of the urogenital mesenchyme, stromal differentiation is in 
turn dependent on the presence and differentiation state of the developing prostatic epithelium [4, 5].  
 
Ductal canalisation is initiated in the solid epithelial cords from the urethral terminus of the prostatic 
ducts and proceeds distally toward the ductal tips. As the solid epithelial cords canalise, the epithelium 
reorganises into two distinct cell populations with luminal and basal cell lineage.  
 
The epithelial component of the prostate gland (Fig. 1) consists of two cell layers, with a luminal 
secretory- cell layer separated from the basement membrane by a basal layer that exhibits most of the cell 
proliferation and which is believed to contain the stem cell. Mesenchymal–epithelial interactions in 
prostatic development  
 
Organogenesis of the prostate is absolutely dependent on mesenchymal–epithelial interaction, as 
differentiation of both the epithelium and mesenchyme. Development of the prostate is dependent on 
inductive signals from the mesenchyme [6], and these prostatic inducing signals emanate from spatially 
discrete areas within the urogenital sinus mesenchyme [7, 8].  
 
The outcome of epithelial–mesenchymal interactions is dependent not only on the source of the 
inducing mesenchyme, but also on the germ layer origin and responsiveness of the epithelium [9]. 
Although mesenchyme induces and specifies the differentiation of the epithelium, developmental end 
points induced by mesenchyme are limited by the developmental repertoire of the germ layer origin of the 
epithelium.  
 
While mesenchyme induces epithelial differentiation, the epithelium in turn induces smooth muscle 
differentiation in the mesenchyme. Indeed, both differentiation and morphologic patterning of smooth 
muscle in the prostate are regulated via cell–cell interactions with epithelium.  
 
Although mesenchymal–epithelial interactions play a fundamental role in development of the prostate, 
the overall developmental process is elicited by androgens, which regulate prostatic development, growth 
and function via androgen receptors.  
 
During foetal and prepubertal development, androgens act on the prostatic mesenchyme to induce 
ductal budding, epithelial proliferation and growth of solid epithelial cords into the mesenchyme. When 
the ducts canalise, the luminal and basal epithelial cells undergo cytodifferentiation [10, 11].  
 
  
 
 
 
Fig. 1a New cells are formed in the distal segments of the ducts whereas the intermediate section is secretory in function.  TA , 
transit amplifying;  NE , neuroendocrine. Adapted from Ref. [99]. b Prostatic ducts arborise throughout the gland and terminate in 
acini. Adapted from Ref. [100]  
Prostate stem cells  
Stem cells are clonogenic cells with self-renewal and differentiation properties, which may represent a 
major target for genetic damage leading to prostate cancer and benign prostatic hyperplasia. Stem cells 
remain poorly characterised because of the absence of specific molecular markers that permit us to 
distinguish them from their progeny, the transit amplifying cells, which have a more restricted 
proliferative potential (Fig. 2).  
  
 
 
 
Fig. 2 Prostate stem cell lineage. Adapted from Ref. [101] 
Early evidence for stem cells in the prostate came from a set of experiments involving androgen 
withdraw- al from both human and rat prostate [12–14]. The existence of stem cells in the prostate is 
probably best illustrated by animal studies investigating the effect of androgen on the prostate. Castration 
leads to rapid involution of the gland, but once androgen levels are re- stored, the gland completely 
regenerates. As this cycle of involution–regeneration can be repeated many times, a population of long-
lived, prostatic epithelial stem cells must exist [15].  
 
It has been reported that two populations of cells capable of regenerating prostatic tissue in an in vivo 
prostate reconstitution assay are present in different regions of prostatic ducts. The first population (with 
considerable growth potential) resides in the proximal region of ducts and in the urethra, and the survival 
of these cells does not require the presence of androgens. The second population (with more limited 
growth potential) is found in the remaining ductal regions and re- quires androgen for survival [16] (Fig. 
3). 
  
 
 
 
Fig. 3 Location of stem cells 
 
 
 THE FIRST POPULATION RESIDES IN THE PROXIMAL REGION AND 
THE URETRA 
 
 Cells from the proximal region of ducts as well as urethral cells have 
considerably greater in vivo regenerative potential than do cells from 
other ductal regions. 
 Some epithelial cells survived and formed small ductal structures in the 
absence of androgen. 
 Primitive cells in the proximal region is unaffected by androgen levels, 
indicating that cells in this region survive androgen ablation. 
 Cells in the proximal region can survive prolonged periods of androgen 
deprivation and retain full regenerative potential and that urethral cells 
have similar properties. 
 
THE SECONDS POPULATION (WITH MORE LIMITED GROWTH 
POTENTIAL) IS FOUND IN THE REMAINING DUCTAL REGIONS 
 
 Survival of these cells requires the presence of androgens. 
 Involution of the gland is accompanied by the enrichment of those cells 
with proliferative potential in the remaining regions of ducts, whereas 
castration does not affect the proportion of cells capable of forming 
prostatic tissue in the proximal. 
 Castration enriches for cells with a primitive phenotype in the remaining 
region of ducts, indicating that the more mature cells die during 
involution. 
 
 
The proximal region of mouse prostatic ducts is enriched in cells exhibiting stem cell-like properties, 
namely quiescence, a high proliferative potential, and the ability of single cells to generate progeny of 
more than one lineage [17]. These cells express Sca-1 [18, 19] and are maintained in a quiescent state by 
high levels of active transforming growth factor β (TGF- β) [20]. The different regions of prostatic ducts 
are heterogeneous in terms of morphology, telomerase expression and levels of TGF- β signalling [15, 20, 
21].  
Stem cell markers  
Evidence for the stem cell hierarchy in prostate epithelium came from the study of the expression 
patterns of various markers of differentiation [22–25].  
 
Normal prostate have a basal cell phenotype with expression of CD133, high levels of integrin α2β1, 
and keratins K5 and K14. These cells give rise to transit-amplifying populations that still have high 
integrin expression but no longer express CD133.  
 
Basal cells express keratins K5 and K14 together and the anti-apoptotic protein, bcl-2, whereas 
luminal cells express K8 with K18, CD57, androgen receptor (AR) and the secretory proteins, PSA and 
prostatic acid phosphatase. Neuroendocrine cells arise from differentiation of normal basal cells and have 
a complex marker expression pattern of basal and luminal keratins, together with secretion of 
chromogranin A and serotonin.  
 
CD133 expression was restricted to a small population of cells within the basal layer, but was 
randomly located throughout acini [26]. High surface expression of integrin α2β1 has been shown to be 
associated with stem cells in the prostate.  
  
In human prostate, stem cells can be distinguished from transit amplifying cells (daughter cells that 
have a more limited proliferative capacity), by two- to three- fold higher surface levels of integrin α2β1 
[23]: these cells (which make up 3% of the total basal population) are also randomly located throughout 
acini [23]. In contrast, others found that stem cells (label-retaining cells) in the rodent prostate are 
concentrated in the proximal region of the prostatic ducts [27–29] 
 
In conclusion, a subpopulation of α2β1 basal cells express the CD 133 antigen and this expression 
correlates with a high proliferative potential and ability to re- generate a fully differentiated prostatic 
epithelium.  
 
The WNT signalling pathway  
The Wnt pathway directs embryonic growth [30], governing processes such as cell fate specification, 
proliferation, polarity and migration. It is also implicated in maintenance of stem cell populations.  
 
There are 19 human Wnt genes [31]. Historically, they have been grouped into two classes, canonical 
and noncanonical. Canonical Wnt family members stabilise β -catenin, thereby activating transcription of 
Tcf/LEF- target genes. Noncanonical Wnt family members activate other signalling pathways, such as the 
planar-cell- polarity pathway, which guides cell movements during gastrulation [32], and the Wnt/Ca
2+
 
pathway [33]. In some instance, noncanonical Wnt antagonise the canonical pathway [34].  
 
Wnt proteins, a large family of cysteine-rich secreted ligands, bind to a class of seven-pass 
transmembrane receptors encoded by the frizzled genes [35] transducing a signal to the cytoplasmic 
protein Dishevelled (Dvl) [36], which is recruited to the membrane, forms a complex with Axin [37] and 
induces its dephosphorylation [38]. Axin (product of the gene AXIN1) acts as a scaffold protein 
maintaining the configuration of a complex involving APC (encoded by the Adenomatous Polyposis Coli 
gene) [39] and β -catenin (encoded by CTNNB1) [40] and facilitating phosphorylation of both APC [41] 
and  β -catenin [42] by glycogen synthase kinase 3 β (GSK3 β) (Fig. 4).  
 
 
 
Fig. 4 General characteristics and components of the Hh and Wnt signalling pathways. *oncogene, **tumour suppressor. + and – 
indicate a positive and negative action, respectively. Adapted from Ref. [102] 
 
  
The presence of a Wnt ligand at the transmembrane receptor Frizzled (Frz) activates the cytoplasmic 
protein Dishevelled, which dephosphorylates axin. This de- creases the capacity of Axin to form 
complexes with APC and β -catenin. Conductin, a protein with structural homology to axin and encoded 
by the gene AXIN2 [43], can function in a similar way to axin in this protein complex [44]. 
Phosphorylation of β -catenin by GSK3 β , and hence degradation of β -catenin by ubiquitin, is de- 
creased. Cytoplasmic β -catenin thus accumulates and is translocated to the nucleus [45], where it 
associates with members of the T-cell factor (Tcf) and lymphoid enhancer factor (LEF) family of 
transcriptional factors [46]. The β -catenin–Tcf/LEF complex activates transcription of target genes 
including c-MYC [47], c-jun and fra-1 (components of the AP-1 transcription complex) urokinase-type 
plasminogen activator receptor (uPAR) [48], and the metalloproteinases matrilysin [49], MMP-26 [50] 
and cyclin D1 [51].  
 
In summary, activation of the pathway by the presence of a Wnt molecule on the cell surface receptor 
de- creases phosphorylation of β -catenin by the APC/ axin/GSK3 β complex. β -Catenin is thus not 
degraded, and accumulates in the nucleus, where it stimulates transcription of a variety of cancer-
associated genes.  
The Hh signalling pathway  
The hedgehog pathway plays a critical role in embryonic development [52]. The hedgehog signalling 
pathway has become widely recognised as one of the major mechanisms for cell–cell communication and 
tissue polarity.  
 
Various studies have now demonstrated the function of Hh signalling in the control of cell 
proliferation, especially for stem cells and stem-like progenitors. Thus, depending on timing and context, 
Hh growth factors are capable of regulating cell proliferation especially of pre- cursors or stem cells, and 
cell differentiation.  
 
Secreted Hh molecules bind to the receptor patched, thereby alleviating PTC-mediated suppression of 
smoothened (Smo), a putative seven-transmembrane protein. Smo signalling triggers a cascade of 
intracellular events, leading to activation of the pathway through Gli-dependent transcription. The 
hedgehog receptor Ptch1 is also a target gene of this pathway, which forms a negative feedback 
mechanism to maintain the pathway activity at an appropriate level in a given cell.  
 
A simplified description of the Hh pathway includes de Hh ligands, their receptor and a few of the 
molecules that transduce the signal. In mammals there are three distinct Hh ligands with different patterns 
of expression: Sonic Hedgehog (Shh), Indian Hedgehog (Ihh) and Desert Hedgehog (Dhh). All three Hh 
ligands bind the transmembrane receptor Patched 1 (Ptch1) (Fig. 3).  
 
In the absence of Hh ligand, Ptch1 inhibits a second transmembrane protein Smoothened (Smo). Hh 
binding to Ptch1 relieves the repression of Smo and allows Smo to further transduce the Hh signal. This 
Hh signalling results in the activation of the Gli family of transcription factors: Gli1, Gli2 and Gli3. Gli1 
and Ptch1 as well as the gene encoding the Hedgehog interacting protein (Hip) are Hh response genes, 
and their expression has been used as evidence for active Hh signalling. Expression of Ptch1 or Hip starts 
a negative feedback loop that shuts down Hh signalling by sequestering Hh ligand. In the cytoplasm the 
Suppressor of Fused (Su(fu)) protein also inhibits transduction of the Hh signal [52].  
  
Shh and prostate development  
The role of Shh in regulating induction, proliferation and differentiation of the developing mammalian 
prostate has been studied most extensively in mouse and rat models: good evidence exists that Shh is 
required for ductal patterning in the developing prostate.  
 
Development of prostate requires hedgehog signalling. Although the initial formation of prostate buds 
does not require sonic hedgehog signalling, Shh is critical for maintaining appropriate prostate growth, 
proliferation and tissue polarity [53–56]. In the adult prostate, however, the activity of the hedgehog 
pathway is quite low.  
 
Epithelial buds grow and form the prostate ducts. The prostate ducts will elongate and branch 
extensively both prenatally and postnatally until the final elaborate branching structure of the mature 
prostate is achieved. Hh function in the prostate seems to centre on the establishment of ductal branching. 
Shh expression begins in the epithelial layers of the rodent urogenital sinus and concentrates at areas of 
epithelial budding [57]. Levels of Shh transcripts continue to be elevated as epithelial invaginations 
become ductal buds. During duct elongation, Shh transcripts localise at the growing distal tips [57–59].  
 
Expression of Shh and activation of the Hh pathway appear to be required for ductal budding and 
branching [60].  
The WNT pathway and prostate cancer  
The Wnt signalling pathway is aberrantly activated in many tumour types, including those of the 
prostate, in which β -catenin accumulates in cell nuclei and acts as a transcriptional coregulator for the 
androgen receptor. Dysfunction of the Wnt pathway in prostate cancer has been assessed in laboratory 
studies, but there are limited published data pertaining to the incidence of mutations in this pathway.  
 
Upregulation of Wnt-1 was demonstrated in patients with advanced prostate carcinoma [61] and 
overexpression of the Wnt-5A messenger RNA (mRNA), a member of the Wnt ligand family, was found 
in one set of prostate tumours [62]. WNT11 expression is elevated in hormone-independent prostate 
cancer cell lines. Additional analysis indicated that WNT11 expression is also elevated in high-grade 
prostatic tumours and in hormone-independent xenografts (Table 1).  
Table 1 Wnt expression during prostate cancer progression 
 
Prostate cancer cell lines (in vitro cultures) 
 WNT 11 expression was found to be low or absent in hormone-dependent cell lines. 
 WNT5B, WNT8B and WNT11 were more highly expressed in androgen-independent derivative cell line. 
 WNT10B, like WNT11, was more highly expressed in the androgen-independent prostate cancer cell lines. 
 WNT7B and WNT14 were more highly expressed in AR-negative prostate cancer cell lines. 
 WNT16 expression was more highly expressed in androgen-dependent cell line. 
 
Prostate tissue samples 
 WNT11 expression was elevated in all cases that were Gleason grade 7 or above. 
 WNT11 was expressed at low levels in nonmalignant cases and in three of three Gleason sum score 6 cases. 
 
Xenograft tumour (CWR22) transplantation 
 WNT11 expression increases during the transition from androgen-dependent to androgen-independent prostate cancer in vivo 
 
 
Results indicate that the expression WNT11 correlates well with hormone-independent growth of prostate cancer cells; increased 
WNT11 expression accompanies the transition to androgen-independent prostate cancer; WNT11 expression is increased in 
aggressive or poorly differentiated prostate cancer [79] 
  
Prostate cancer has been shown to carry mutations in β-catenin, APC and, interestingly, in β TrCP 
[63–65]. Loss of heterozygosity (LOH) was found in the APC locus in 15% of prostate tumours [66], or 
in three of seven tumours [67]. In studies of tumours from Japanese men, APC gene mutation was found 
in none of 18 tumours and 1 of 36 tumours [68, 69]. LOH [67] and mutation [68] of the APC gene have 
been detected in some tumour samples, but another group could find no APC mutations [69].  
 
As each of these alterations occurred in about 10% of cases and were mutually exclusive, activating 
mutations of the Wnt pathway appear to play a role in at least 30% of prostate tumours.  
 
The expression of E-cadherin, β-catenin and GSK3 β is diminished in prostate cancer cell lines of 
greater invasive potential [70]. Expression of β -catenin in bone metastases appears to be downregulated, 
compared with that seen in corresponding primary tumours in patients with untreated prostate cancer [71]. 
Functional interaction of β -catenin with the androgen receptor was also shown, indicating a cross-talk of 
both pathways in the development of prostate cancer [64]. 
 
Interestingly, the androgen receptor was shown to bind to β-catenin [72, 73] and to transport β -
catenin into the nucleus [74]. Furthermore, transcriptional activity of the androgen receptor was 
augmented by β-catenin [72, 73], while androgens can block Tcf/ β -catenin- mediated transcription in 
prostate cancer cells [75]. This indicates an interplay of Wnt signalling and androgen-dependent 
pathways, which might be of relevance for prostate cancer development and progression.  
 
In an immunohistochemical study, β-catenin staining was abnormal in 23% of 122 radical 
prostatectomy specimens, compared to 38% of 90 specimens from transurethral prostatectomies 
performed in patients with hormone-refractory prostate cancer [76]. This supports the hypothesis that 
alterations in the Wnt pathway may contribute to progression of prostate cancer to androgen 
independence. Sublines of apoptosis-resistant LNCaP cells showed increased nuclear β -catenin 
expression and increased Tcf/LEF transcription compared to the parent lines [77].  
 
Although, to date, the detection of reproducible genetic lesions in the earliest stages of prostatic 
intraepithelial neoplasia (PIN) is rare, in transgenic animal models stabilised β-catenin induced lesions 
reminiscent of prostatic intraepithelial neoplasia [78]. Expression of a mutant form of β-catenin produces 
lesions with histological appearances similar to PIN, the putative precursor of prostate cancer, as early as 
10 weeks of age, but these lesions did not progress to invasion or metastasis in animals up to 5 months of 
age [79].  
The Shh pathway and prostate cancer  
The hedgehog pathway plays a critical role in the development of prostate branching. Because data 
implicating this pathway in cancer are relatively recent, it is too early to know if alternations occur in 
prostate cancer. To date, there are few reports in the prostate cancer literature.  
 
Activation of the Hh pathway occurs frequently in advanced human prostate cancer: high levels of Hh 
target genes, Ptch1 and Hh interacting protein (Hip) are detected in over 70% of prostate tumours with 
Gleason scores of 8–10, but in only 22% of tumours with Gleason scores of 3–6 [80].  
 
Increased protein expression of Ptch1 and Hip indicates activation of the hedgehog pathway. Thus, 
activation of the hedgehog pathway, as indicated by elevated Ptch1 and Hip expression, is associated with 
loss of Su(fu) expression or elevated Hh expression. Target genes of the hedgehog pathway, Ptch1 and 
Gli1, were all elevated in these tumours, confirming activation of the hedgehog pathway in these tumours. 
Thus, Su(fu) inactivation appears to contribute to activation of hedgehog signalling in prostate tumours. 
In total, 11 of 27 Ptch1- positive prostate cancer specimens have no detectable Su(fu) protein. Prostate 
cancers with low Gleason scores, however, frequently have detectable Su(fu) protein, suggesting that loss 
of Su(Fu) protein may be associated with prostate cancer progression.   
  
There are several mechanism by which the hedgehog pathway in these prostate tumours can be 
activated, including loss of Su(fu) or overexpression of Hh. In humans the Su(fu) gene is localised at 
chromosome 10q24, a region with frequent LOH in several types of cancer, including prostate cancer [77, 
81, 82]. Of note, the human Su(fu) gene product, a repressor of Gli activity, maps to the 10q24 locus, and 
thus could be targeted for deletion or codeletion along with PTEN (located at 10q23) in a number of 
prostate cancers [83].  
 
Also, Shh expression varies from tumour to tumour, which may result from the heterogeneity of 
prostate cancer. The heterogeneous nature of prostate cancer makes it difficult to screen prostate cancer 
specimens for Su(fu) mutations; some prostate tumours had no detectable Su(fu) protein expression while 
others contained high levels of Shh protein expression [84].  
Clinical significance  
The requirement of Shh for prostate development as well as the misregulation of Shh signalling in a 
variety of cancers suggests that expression of Shh and/or activation of the Hh pathway might be critical 
for the develop- ment of prostate cancer. Furthermore, it is interesting to note that multiple components of 
the Hh pathway are present within chromosomal regions associated with susceptibility to human prostate 
cancer [84–91].  
 
Prostate cancer also is estimated to have a significant genetic component [92] and familial genetic 
map- ping studies have identified a series of chromosomal regions that are associated with familial 
prostate cancer risk. These include regions on chromosomes 1p36, 1q24-25, 8p22, 17p and Xq27-28 that 
have been identified in individual cohort studies [92–95]. Additional chromosomal regions that may 
contain prostate cancer susceptibility genes have been recently published and include regions on 
chromosomes 5q12, 8p21, 15q11, 17q21 and 22q12 [91].  
 
Analysis of data from genetic studies of familial prostate cancer showed that regions implicated in 
prostate cancer susceptibility contained the genes coding for Hh pathway components, including Gli1, 
Gli3, Smo and Su(fu) [96–98].  
 
This is coupled with data that indicate that the hedgehog pathway is present and expressed in human 
prostate tumours. Analysis of Shh protein immunoreactivity in both normal prostate tissues and tumours 
demonstrated an upregulation of Shh in prostate tumours, a finding that correlated with the more 
aggressive tumours, with the Shh-positive tumours having a higher Gleason grade [99, 100]. A meta-
analysis of the combined data on Shh and its downstream signalling molecules [99, 100] reveals that 
while Shh is present in both benign and malignant prostate epithelial cells, the downstream targets Ptch 
and Gli1 are preferentially activated in metastatic prostate tumours.  
 
Shh signalling in prostate cancer reveals that all the advanced metastatic prostate cancers studied to 
date have activated the Shh signalling pathway: myriad mechanisms exist that could induce activation of 
the pathway even in the absence of the ligand. These would include the upregulation or activating 
mutations in the Hh receptor Ptch or its co-receptor Smo, or the down- stream signalling Gli proteins. 
There is now a growing knowledge that similar mechanisms are in place regarding the Hh pathway and 
prostate cancer (Fig. 5).  
  
 
 
 
Fig. 5 Prostate cancer changes and the Hh pathway. Shh, PTCH, Hip and Gli 1 are molecules overexpressed. →, stimulation; ⎯⎯, 
inhibition. Adapted from Ref. [103] 
Analysis of tissue samples has clearly demonstrated the correlation between Shh pathway activation 
and the presence of prostate cancer. Examination of five different human prostate cancer cell lines 
(LNCaP, PC3, DU145, TSU and 22RVI) revealed high levels of Gli1 and Ptch1 expression in all lines, 
indicating activity of the Hh pathway [99, 100].  
 
Expression studies in prostate tissue samples and prostate cancer cell lines made a strong case for the 
importance of Shh signalling in prostate cancer. The key question then became how activity of the 
pathway affects cellular behaviours associated with tumorigenesis and metastasis.  
 
It has been demonstrated the dependence of prostate cancer cell proliferation on Shh-Gli pathway 
activity. The data suggest activation of the pathway at different levels in primary prostate tumours and 
cell lines derived from metastatic lesions. These findings, together with the involvement of this pathway 
in normal prostate development and growth, indicate that the normal patterning role of Shh-Gli signalling 
is deregulated in cancer. In contrast, Gli2 and Gli3 do not appear to be consistently expressed in prostate 
cancer cells.  
 
The establishment of Hh signalling as a major player in the pathogenesis of advanced prostate cancer 
opens the door to a wide array of basic and translational questions and issues to be resolved. For example, 
clinical studies might ask whether some measure of Hh signalling activity could provide a more accurate 
diagnosis of prostate cancer, and identify those for whom there would be an obvious treatment – 
inhibition of the Hh pathway.  
Conclusions  
Over the past several years, it has become clear that, similar to what occurs in the haematopoitec 
system, epithelial tissues are subject to continuous remodelling and renewal in a tightly regulated manner. 
This tissue renewal involves a hierarchy of cells including slowly proliferating stem cells, rapidly 
proliferating transit-amplifying cells and various terminally differentiated cells with specialised functions. 
These putative tissue-specific stem cells have several properties that make them appealing as targets for 
transforming genetic events. In particular, they are characterised by a capacity for un- limited self-
renewal, and they retain the ability to generate a diverse set of differentiated progeny.  
  
All adult tissues are made up of lineages of cells consisting of tissue-determined stem cells and their 
progeny (transit-amplifying cells), which provide cellular lineages producing many cells that differentiate 
to the mature functioning cells of the tissue. Each tissue has an individual rate of normal tissue renewal.  
 
In any case, all tissues have stem cells, but these stem cells do not all have identical possibilities 
(potentials) for producing different cell types. Normal stem cells have some properties that are associated 
with malignant cells. By definition, normal stem cells retain a large capacity for self-renewal and have the 
ability to migrate to distant parts of the body, where they not only survive but also frequently establish 
new colonies. These inherent properties of normal stem cells suggest that fewer or different steps may be 
necessary to produce and transform cancer stem cells as opposed to more differentiated cells. This 
observation suggests that any cell of a lineage that is not terminally differentiated can still proliferate and 
can potentially give rise to cancer.  
 
In particular, because the terminally differentiated cells that compose most epithelial tissues rarely 
proliferate and often are continuously replaced in epithelial linings, the probability that an individual cell 
will accumulate a set of mutations necessary to create a tumour is small.  
 
The identification of cells with stem-like properties in human tumours raises the question of whether 
such cells are the target population in which cancer initiation occurs. Although stem cells share some 
attributes of human tumours, such cells represent only a minuscule fraction of the cells that compose each 
tissue. Within established tumours, the great majority of the cancer cells cannot sustain the lesion or 
establish it elsewhere in the body.  
 
Only a few cells within the tumour, the cancer stem cells, are tumorigenic and possess the metastatic 
phenotype. In general, cancer stem cells resulting from mutations in stem/progenitor cells most likely 
undergo un- controlled proliferation.  
 
Cancer develops from normal tissues through the accumulation of genetic alterations that act in 
concert to confer malignant phenotypes. Although some of the genes that, when mutated, initiate tumour 
formation and drive cancer progression have been identified, the identification of the cell population(s) 
susceptible to such transforming events remains undefined for the majority of human cancers.  
 
The precise relationship of normal stem cells to cancer stem cells remains undefined, and it remains 
possible that cancer stem cells only mimic certain stem cell phenotypes or that cancer stem cells reflect an 
altered early transit-amplifying cell.  
 
The signal that controls which daughter cell of an adult stem cell remains a stem cell and which begins 
the process of determination may be mediated through a number of signalling pathways including the 
Oct-4, Wnt/β-catenin, Notch, bone morphogenic protein (BMP), Janus family kinase or signalling 
pathways, etc.  
 
In addition, recent work suggests that many signalling pathways thought to be involved in the 
maintenance of normal stem cells are found to be mutated in human cancers, including those regulated by 
Wnt,  β-catenin, PTEN, TGF- β , Hedgehog and Notch.  
 
The gene encoding Wingless, a founding member of the Wnt family of growth factors, was originally 
uncovered in the same series of genetic screens that produced mutations in Hh. The mammalian Wnt, on 
the other hand, was originally identified as an oncogene. Recently, studies have suggested that Wnt 
signalling activates the proliferation of precursor cells to produce tumours. Wnt pathway dysfunction is 
an important component of prostatic tumorigenesis. 
 
Wnt/β-catenin cell activation pathway is active in maintaining proliferation at an early stage of 
differentiation and may have a similar role in cancer cells. Wnt signalling affects the orientation of the 
chromosomes during mitotic division, and abnormalities in the orientation might contribute to mitotic 
disjunctions typical of cancer cells [26]. In general, Wnt/β-catenin signalling activates proliferation and 
inhibits apoptosis, the classic hallmarks of cancer cells.  
 
Hedgehog signalling pathway regulates cell proliferation, tissue polarity and cell differentiation during 
nor- mal development. The Hedgehog family of growth factors activates a highly conserved signalling 
system for cell–cell communication. Abnormal activation of the Hedgehog pathway has been 
demonstrated in advanced prostate cancer and demonstrated that autocrine signalling by tumour cells is 
required for proliferation, viability and invasive behaviour. The direct link between Hh pathway activity 
and in vivo prostate tumour growth and metastasis is incredibly exciting. The level of Hedgehog activity 
correlates with the severity of the tumour and is both necessary and sufficient for metastatic behaviour.  
 
Thus, Hedgehog signalling represents a novel path- way in prostate cancer that offers opportunities for 
prognostic biomarker development.  
 
Perhaps more promising is the potential to target specific signalling pathways required for stem-cell 
function. The most likely suspects, on the basis of current thinking, are the Hh and Wnt pathways, both of 
which have oncogenic potential based on known mutations in pathway components found in several 
human tumours.  
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